# OnCo record asciminib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/asciminib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "asciminib" ;
  schema:name "Asciminib"@en ;
  schema:description "Asciminib is a BCR::ABL1 blocker that binds a different pocket from every other TKI, approved for all newly diagnosed chronic myeloid leukaemia in 2024 and now being tested in Ph-positive ALL."@en ;
  schema:url <https://onco.cc/drugs/asciminib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Asciminib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27074535> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Asciminib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule allosteric ABL1 inhibitor (STAMP)" ;
  schema:alternateName "Scemblix" ;
  onco:approval "US 2021: CML after ≥2 prior TKIs; T315I CML", "US 2024: Newly diagnosed Ph+ CML in chronic phase (ASC4FIRST)" ;
  onco:acceleratedApproval "US 2021-10-29: Adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)", "US 2024-10-29: Treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)." ;
  onco:acceleratedApprovalConfirmed "US 2022-10-12: Adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)" ;
  onco:related <https://onco.cc/biomarkers/bcr-abl1-t315i/> ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/cml-chronic-phase/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/>, <https://onco.cc/targets/abl1/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:terms <https://onco.cc/terms/ph-positive-all/> ;
  onco:trials <https://onco.cc/trials/nct07354074/>, <https://onco.cc/trials/nct06514534/>, <https://onco.cc/trials/nct04971226/>, <https://onco.cc/trials/nct04925479/>, <https://onco.cc/trials/nct05384587/>, <https://onco.cc/trials/nct05456191/>, <https://onco.cc/trials/nct07387926/> .